Clinical Trial:

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study

This is an open label, Phase 1b/2a study designed to test the biological and immunological activity of an antibody called AFM13 when given intravenously.  


There are 6 groups called cohorts, each cohort consists of 3 research subjects who will be treated with different doses and dose regimens of AFM13. The purpose of this study is to see if AFM13 is safe and effective in the treatment of research subjects with relapsed or refractory cutaneous lymphomas that are CD30 Positive following conventional treatment.